Prognostic Value of the Modified Model for End-Stage Liver Disease (MELD) Score Including albumin in acute heart failure

Shengen Liao  
Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital

Xinyi Lu  
Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital

Iokfai Cheang  
Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital

Xu Zhu  
Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital

Ting Yin  
Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital

Wenming Yao  
Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital

Haifeng Zhang  
Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital

Xinli Li  
Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital  
https://orcid.org/0000-0002-7889-6359

Research article

Keywords: Model for End-stage Liver Disease, Mortality, Albumin, Acute heart failure

DOI: https://doi.org/10.21203/rs.3.rs-120667/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: Liver and renal function evaluated by the model for end-stage liver disease (MELD) score, the MELD excluding the international normalized ratio (MELD_XI) score and the MELD including sodium (MELD_sodium) score have been considered predictors of adverse events for patients with acute heart failure (AHF). However, the prognostic value of the MELD including albumin (MELD_albumin) score in patients with AHF has not been assessed.

Methods: A total of 466 patients with AHF were prospectively evaluated. We compared the accuracy of the 4 MELD score formulas using the time-dependent receiver operating characteristic (ROC) curve and corresponding areas under the curve (AUC).

Results: During a median follow-up period of 34 months, 196 deaths occurred. In the fully adjusted Cox regression model, standardized hazard ratios with 95% confidence interval expressing the risk of all-cause mortality were 1.22 (1.06–1.40), 1.20 (1.04–1.39), 1.21 (1.05-1.41) and 1.23 (1.06–1.42) for MELD, MELD_XI, MELD_albumin and MELD_sodium scores, respectively. The MELD_albumin score showed the best prognostic accuracy (AUC = 0.658) for the prediction of long-term all-cause mortality, followed by the MELD_sodium score (AUC = 0.590), the MELD score (AUC = 0.580), and the MELD_XI score (AUC = 0.544).

Conclusions: The MELD_albumin score performs more accurately than the MELD score and the other modified MELD scores for predicting the risk of all-cause mortality in patients with acute heart failure.

Background

Heart failure (HF) is a common disease and is associated with considerable morbidity and mortality worldwide [1]. With the increase in HF patients, HF has recently become a serious health problem [2]. Acute heart failure (AHF) is a complex syndrome characterized by worsening heart failure symptoms. The predominant clinical profile in most patients with AHF is congestion and hypoperfusion, which can lead to organ dysfunction and increase the risk of mortality.

Liver and renal dysfunction are often complicated in patients with acute heart failure [3]. Complicated interaction between heart, kidney, and liver has been an object of interest for a long time. In that sense, simple score capable of quantitating the severity of multiorgan failure is attractive. Biomarkers that reflect liver and kidney function are often used to predict adverse clinical outcomes in patients with AHF [4, 5]. The model for end-stage liver disease (MELD) score evaluating liver and renal function was considered a reliable predictor for the risk of adverse events in AHF patients [6]. Several studies also focused on the effects of modified MELD versions, such as the MELD excluding the international normalized ratio (MELD_XI) score [3, 7], and the MELD including sodium (MELD_sodium) score [8], on the prognosis of acute heart failure. However, the prognostic value of the MELD including albumin (MELD_albumin) score, which includes the serum value of albumin rather than the international
normalized ratio, in AHF patients is still unknown. Moreover, it is largely unknown whether one of the MELD scores or its 3 modifications is superior for predicting the risk of mortality.

Accordingly, we aimed to assess the prognostic role of the MELD_albumin score in patients with AHF over a long-term follow-up. In addition, we further aimed to compare the accuracy of the MELD_albumin score with other well-established objective MELD and modified MELD scores for predicting the risk of death in patients with AHF.

Methods

Study subjects

We analyzed data from the registry study of AHF in China: the diagnostic standards, risk stratification, and clinical outcomes of acute heart failure (registration number: ChiCTR-ONC-12001944), which is a multicenter, observational, prospective cohort study. From March 2012 to June 2017, 590 patients with AHF were assessed for eligibility. The diagnosis of AHF was based on clinical signs and symptoms and according to the guidelines, and each patient received standard clinical evaluation and guided recommended treatment [9]. Patients with severe vascular disease or coronary artery disease requiring urgent surgery (n = 46) or who withdrew informed consent (n = 2) were excluded from the study. We also excluded patients with end-stage renal disease requiring dialysis and patients who were already taking oral anticoagulants upon admission (n = 46). Finally, a total of 496 patients were included in this study (Fig. 1).

Meld Score And Its 3 Modifications

The standard MELD [10] score and 3 modifications (MELD_XI [11], MELD_albumin [12] and MELD_sodium [13]) were calculated according to the formulas presented in Fig. 2. If the total bilirubin or creatinine level was less than 1 mg/dl, their lower limit was assumed to be 1 mg/dl to avoid negative scores.

Data Collection

Data on age, sex, body mass index (BMI), history of diabetes mellitus, hypertension, heart rate, blood pressure on admission, New York Heart Association (NYHA) class, etiology of heart failure and prescribed medicine were recorded. Left ventricular ejection fraction (LVEF) was measured according to the modified Simpson’s method.
Blood samples to test for serum sodium, potassium, albumin, creatinine, uric acid, alanine aminotransferase (ALT), aspartate aminotransaminase (AST), total bilirubin, the international normalized ratio (INR) and pro-brain natriuretic peptide (proBNP) concentrations were obtained on admission.

Endpoints And Follow Up

The primary endpoint was all-cause mortality. The secondary endpoint was cardiovascular mortality due to AHF. Cardiovascular mortality was coded according to the International Classification of Diseases, 10th Revision (ICD–10). All patients were followed-up in our cardiology department at 3, 6, and 12 months after discharge and then every 6 months thereafter.

Statistical analysis

Categorical variables are presented as percentages. Continuous variables are presented as the mean (standard deviation, SD) or median (interquartile) according to the distribution. Characteristics were compared according to survival status using the independent Student’s t-test, the Wilcoxon test and the chi-square test, as appropriate. Comparisons between MELD and its 3 modifications were performed by the paired Wilcoxon test. Pairwise Spearman correlation analysis was used to investigate the relationships among MELD score and its 3 modifications.

We evaluated the association between the MELD scores and each of our outcomes using Cox proportional hazards regression with 1-SD increments in the continuously distributed MELD score and its 3 modifications. Univariate Cox regression analysis for all-cause mortality indicated that variables with statistically significant differences (P < 0.05) were used to derive the final model. The statistically significant variables were assessed in terms of the outcomes of all-cause mortality and cardiovascular mortality. For each outcome, we calculated unadjusted hazard ratios (HRs); HRs adjusted for age and sex (Model 1); and HRs adjusted for age, sex, NYHA class, LVEF, proBNP, systolic blood pressure and diastolic blood pressure along with corresponding 95% confidence intervals (CIs).

The predictive performance of the MELD scores was calculated according to the time-dependent receiver–operator characteristic (ROC) curves [14] and the corresponding areas under the curve (AUCs). Comparisons of the AUCs were performed with a DeLong test [15]. All analyses were performed using R software version 3.6.0 (R Foundation for Statistical Computing, Vienna, Austria). A P value < 0.05 was considered statistically significant.

Results
Baseline characteristics

Thirty patients were lost to follow-up. A total of 466 patients with AHF were included in the final analysis. After a median follow-up of 34 months, 196 (42.1%) deaths occurred, and 158 (33.9%) patients died of cardiovascular causes. At baseline, patients who died were older than survivors and were more often female. Notably, patients who died had more severe clinical symptoms, lower systolic or diastolic blood pressure, lower serum albumin, lower LVEF and higher proBNP (Table 1).
Table 1
Baseline characteristics of the enrolled patients.

<table>
<thead>
<tr>
<th>Variables</th>
<th>All (n = 466)</th>
<th>Deaths (n = 196)</th>
<th>Survivors (n = 270)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>61.8 (25.0)</td>
<td>65.0 (15.5)</td>
<td>59.5 (29.9)</td>
<td>0.019</td>
</tr>
<tr>
<td>Male, %</td>
<td>314 (67.4%)</td>
<td>111 (56.6%)</td>
<td>203 (75.2%)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Diabetes, %</td>
<td>118 (25.3%)</td>
<td>51 (26.0%)</td>
<td>67 (24.8%)</td>
<td>0.768</td>
</tr>
<tr>
<td>Hypertension, %</td>
<td>244 (52.4%)</td>
<td>97 (49.5%)</td>
<td>147 (54.4%)</td>
<td>0.290</td>
</tr>
<tr>
<td>Ischemic heart failure, %</td>
<td>125 (26.8%)</td>
<td>53 (27.0%)</td>
<td>72 (26.7%)</td>
<td>0.928</td>
</tr>
<tr>
<td>NYHA</td>
<td></td>
<td></td>
<td></td>
<td>0.041</td>
</tr>
<tr>
<td>II</td>
<td>57 (21.1%)</td>
<td>24 (12.2%)</td>
<td>81 (17.4%)</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>138 (51.1%)</td>
<td>108 (55.1%)</td>
<td>246 (52.8%)</td>
<td></td>
</tr>
<tr>
<td>IV</td>
<td>75 (27.8%)</td>
<td>64 (32.7%)</td>
<td>139 (29.8%)</td>
<td></td>
</tr>
<tr>
<td>Heart rate, beats/min</td>
<td>85.5 (20.9)</td>
<td>85.1 (21.4)</td>
<td>85.7 (20.6)</td>
<td>0.731</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>127 (22.6)</td>
<td>124 (19.9)</td>
<td>129 (24.2)</td>
<td>0.020</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>78.5 (15.2)</td>
<td>76.0 (12.2)</td>
<td>80.4 (16.8)</td>
<td>0.002</td>
</tr>
<tr>
<td>Potassium (mmol/L)</td>
<td>3.99 (0.51)</td>
<td>3.99 (0.51)</td>
<td>3.99 (0.50)</td>
<td>0.912</td>
</tr>
<tr>
<td>Sodium (mmol/L)</td>
<td>140 (3.9)</td>
<td>139 (4.2)</td>
<td>140 (3.7)</td>
<td>0.086</td>
</tr>
<tr>
<td>Albumin (g/L)</td>
<td>3.66 (0.48)</td>
<td>3.60 (0.49)</td>
<td>3.71 (0.47)</td>
<td>0.025</td>
</tr>
<tr>
<td>Creatinine (mg/dL)</td>
<td>1.16 (0.65)</td>
<td>1.21 (0.61)</td>
<td>1.12 (0.68)</td>
<td>0.131</td>
</tr>
<tr>
<td>Uric acid (mg/dL)</td>
<td>8.13 (2.83)</td>
<td>8.41 (3.06)</td>
<td>7.93 (2.64)</td>
<td>0.070</td>
</tr>
<tr>
<td>ALT (U/L)</td>
<td>27(17–46)</td>
<td>26(15–50)</td>
<td>27(18–44)</td>
<td>0.550</td>
</tr>
<tr>
<td>AST (U/L)</td>
<td>28(22–42)</td>
<td>28(22–48)</td>
<td>28(22–39)</td>
<td>0.162</td>
</tr>
<tr>
<td>INR</td>
<td>1.20 (0.28)</td>
<td>1.22 (0.26)</td>
<td>1.18 (0.30)</td>
<td>0.142</td>
</tr>
<tr>
<td>Total bilirubin (mg/dL)</td>
<td>1.23 (1.03)</td>
<td>1.28 (1.00)</td>
<td>1.19 (1.04)</td>
<td>0.348</td>
</tr>
<tr>
<td>proBNP (ng/L)</td>
<td>2254 (1269–5835)</td>
<td>2873 (1572–7373)</td>
<td>1779 (1087–4601)</td>
<td>&lt; 0.001</td>
</tr>
</tbody>
</table>

Data are presented as mean (SD) or median (interquartile range), or n (%). proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association functional; ALT, alanine aminotransferase; AST, aspartate aminotransaminase; LVEF, left ventricular ejection fraction; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blocker.
### Agreement Of Measurements

Figure 3A presents the estimates of the MELD score and its 3 modifications using the four formulas. The median (interquartile) values of the MELD, MELD_XI, MELD_albumin and MELD_sodium scores were 7.2 (8.5–10.9), 11.3 (9.4–13.8), 12.3 (9.6–15.2) and 8.6 (6.5–12.4), respectively. The MELD_XI and MELD_albumin scores were significantly higher than the MELD score (all \( P \) value < 0.001), and the MELD_sodium score was similar to the MELD score. Pairwise Spearman correlation test was performed among the MELD score and its 3 modifications. MELD correlated better with MELD_XI (\( r \) value = 0.94, \( P < 0.001 \)) than the 2 other modified MELD scores (\( r \) value for MELD_albumin = 0.67, \( P < 0.001 \); \( r \) value for MELD_sodium = 0.72, \( P < 0.001 \)) (Fig. 3B).

### Impact of MELD score and its 3 modifications on mortality

Table 2 shows the main predictors of all-cause mortality by univariate Cox regression analysis. Baseline age, sex, NYHA class, LVEF, proBNP, systolic blood pressure and diastolic blood pressure (\( P \) values < 0.05) were considered potential risk factors for long-term all-cause mortality in patients with AHF. After further adjusting all risk factors at baseline, standardized hazard ratios (HRs) with 95% confidence intervals (CIs) expressing the risk of all-cause mortality were 1.22 (1.06–1.40), 1.20 (1.04–1.39), 1.21 (1.05–1.41) and 1.23 (1.06–1.42) for the MELD, MELD_XI, MELD_albumin and MELD_sodium scores, respectively, and the
corresponding hazard ratios for cardiovascular mortality were 1.30 (1.12–1.50), 1.28 (1.10–1.49), 1.27 (1.07–1.49) and 1.34 (1.14–1.57), respectively (Table 3).
Table 2
Univariate analysis of predictors for all-cause mortality.

<table>
<thead>
<tr>
<th>predictor</th>
<th>HR(95%CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>1.00(1.00, 1.01)</td>
<td>0.016</td>
</tr>
<tr>
<td>Male, %</td>
<td>0.55(0.41, 0.73)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Diabetes, %</td>
<td>1.01(0.74, 1.39)</td>
<td>0.936</td>
</tr>
<tr>
<td>Hypertension, %</td>
<td>0.87(0.66, 1.15)</td>
<td>0.327</td>
</tr>
<tr>
<td>Ischemic heart failure, %</td>
<td>1.12(0.82, 1.54)</td>
<td>0.483</td>
</tr>
<tr>
<td>NYHA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>1.00</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>1.63(1.05, 2.54)</td>
<td>0.031</td>
</tr>
<tr>
<td>IV</td>
<td>2.01(1.25, 3.21)</td>
<td>0.004</td>
</tr>
<tr>
<td>Heart rate (beats/min)</td>
<td>1.00(0.99, 1.00)</td>
<td>0.521</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>0.99(0.99, 1.00)</td>
<td>0.023</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>0.98(0.97, 0.99)</td>
<td>0.001</td>
</tr>
<tr>
<td>Potassium (mmol/L)</td>
<td>1.08(0.81, 1.42)</td>
<td>0.612</td>
</tr>
<tr>
<td>Uric acid (mg/dL)</td>
<td>1.05(0.99, 1.10)</td>
<td>0.057</td>
</tr>
<tr>
<td>ALT (U/L)</td>
<td>1.00(1.00, 1.00)</td>
<td>0.598</td>
</tr>
<tr>
<td>AST (U/L)</td>
<td>1.00(1.00, 1.00)</td>
<td>0.659</td>
</tr>
<tr>
<td>proBNP (ng/L)</td>
<td>1.00(1.00, 1.00)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>LVEF (%)</td>
<td>0.98(0.97, 0.99)</td>
<td>0.001</td>
</tr>
<tr>
<td>Body mass index (kg/M2)</td>
<td>0.98(0.95, 1.00)</td>
<td>0.082</td>
</tr>
<tr>
<td>Antisterone, %</td>
<td>1.13(0.70, 1.81)</td>
<td>0.622</td>
</tr>
<tr>
<td>ACEI/ARB, %</td>
<td>0.94(0.67, 1.31)</td>
<td>0.699</td>
</tr>
<tr>
<td>Beta-blocker, %</td>
<td>0.79(0.57, 1.10)</td>
<td>0.163</td>
</tr>
<tr>
<td>Aspirin, %</td>
<td>1.08(0.82, 1.44)</td>
<td>0.583</td>
</tr>
</tbody>
</table>

NYHA, New York Heart Association functional class; ALT, alanine aminotransferase; AST, aspartate aminotransaminase; LVEF, left ventricular ejection fraction; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blocker.
Table 3
Standardized hazard ratios (95% confidence intervals) of mortality.

<table>
<thead>
<tr>
<th></th>
<th>Unadjusted</th>
<th>Model 1</th>
<th>Model 2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HR(95%CI)</td>
<td>P value</td>
<td>HR(95%CI)</td>
</tr>
<tr>
<td>All cause mortality</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MELD</td>
<td>1.23(1.10–1.38)</td>
<td>&lt; 0.001</td>
<td>1.31(1.16–1.47)</td>
</tr>
<tr>
<td>MELD_XI</td>
<td>1.21(1.08–1.36)</td>
<td>0.002</td>
<td>1.28(1.14–1.45)</td>
</tr>
<tr>
<td>MELD_albumin</td>
<td>1.27(1.13–1.42)</td>
<td>&lt; 0.001</td>
<td>1.31(1.16–1.47)</td>
</tr>
<tr>
<td>MELD_sodium</td>
<td>1.29(1.14–1.46)</td>
<td>&lt; 0.001</td>
<td>1.36(1.19–1.54)</td>
</tr>
<tr>
<td>Cardiovascular mortality</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MELD</td>
<td>1.31(1.17–1.48)</td>
<td>&lt; 0.001</td>
<td>1.39(1.23–1.56)</td>
</tr>
<tr>
<td>MELD_XI</td>
<td>1.29(1.14–1.46)</td>
<td>&lt; 0.001</td>
<td>1.36(1.20–1.53)</td>
</tr>
<tr>
<td>MELD_albumin</td>
<td>1.31(1.15–1.48)</td>
<td>&lt; 0.001</td>
<td>1.35(1.18–1.53)</td>
</tr>
<tr>
<td>MELD_sodium</td>
<td>1.41(1.23–1.60)</td>
<td>&lt; 0.001</td>
<td>1.48(1.29–1.69)</td>
</tr>
</tbody>
</table>

Model 1 was adjusted for age and sex
Model 2 was adjusted age, sex, NYHA class, LVEF, proBNP, systolic blood pressure, diastolic blood pressure.

Prognostic Accuracy

The predictive accuracy of the MELD, MELD_XI, MELD_albumin and MELD_sodium scores was compared using time-dependent ROC curves. If we considered the entire follow-up period, the MELD_albumin score showed the best prognostic accuracy for all-cause and cardiovascular mortality in nearly the entire follow-up period. The quantified AUCs with a four-year cut-off for all-cause mortality outcome were 0.580 (0.509–0.650) for the MELD score, 0.544 (0.476–0.614) for the MELD_XI score, 0.658 (0.591–0.728) for the MELD_albumin score, and 0.590 (0.519–0.661) for the MELD_sodium score. The MELD_albumin score was significantly better than the MELD and the 2 other modified MELD scores for predicting 4-year all-cause mortality risk (all P value < 0.05, Fig. 4).
The quantified AUCs with a four-year cut-off for cardiovascular mortality outcome were 0.617 (0.545–0.689) for the MELD score, 0.580 (0.508–0.652) for the MELD_XI score, 0.663 (0.593–0.734) for the MELD_albumin score, and 0.625 (0.553–0.697) for the MELD_sodium score. The MELD_albumin score was significantly better than the MELD_XI score for predicting the 4-year risk of cardiovascular mortality ($P$ value = 0.009, Fig. 5). However, MELD_albumin showed no significant better than the MELD and MELD_sodium score in predicting 4-year cardiovascular mortality risk.

**Discussion**

To our knowledge, this is the first study providing evidence that liver and renal function evaluated by the MELD_albumin score, beyond standard clinical and demographic parameters, could serve as an important predictor of the prognosis of AHF. Our study also indicates for the first time that evaluating liver and renal function using the MELD_albumin score outperforms evaluation using MELD and other modified MELD scores to predict all-cause mortality in AHF patients. The present data extend the usefulness of modified MELD scores to predict clinical events in patients with AHF.

Our findings are consistent with previous studies reporting the prognostic role of liver and renal function on mortality in patients with AHF [3, 6, 7] and add interesting information to the available literature on this topic. The MELD score and its modifications, which have been widely used as prognostic predictors in patients with liver diseases [10, 12], have recently been shown to be associated with worse clinical outcomes in patients with AHF [3, 6, 7]. In the study conducted by Kim et al. [6], elevated MELD, MELD_XI, and MELD_sodium scores were associated with an increased risk for composite endpoint of death, heart transplantation and ventricular-assist device requirement in ambulatory patients with heart failure (HR was 1.10 (1.06–1.14) for MELD; HR was 1.13 (1.07–1.19) for MELD_XI; HR was 1.10 (1.06–1.14) for MELD_sodium). Another study by Biegus et al. [3] demonstrated that the MELD or MELD_XI score at baseline was predictive of 1-year all-cause mortality in patients with AHF (HR was 1.08 (1.02–1.35) for MELD, HR 1.11 (1.05–1.2) for MELD_XI). Similar results were also found in another study by Biegus et al. [7], in which the MELD-XI score was significantly associated with all-cause death (HR 1.11 (1.04–1.17)). Notably, the MELD score has been shown to identify risk in patients supported with a left ventricular assist device [16] and patients who underwent cardiac surgery [17].

Compared to the previous studies, the difference in hazard ratios of our study may arise from the relatively larger sample size, the longer follow-up duration, the value of the MELD score or its modifications, the definition of the outcome and the cofounding factors we adjusted. Notably, our study not only highlighted the prognostic role of the modified MELD score but also indicated that the MELD_albumin score was superior to the MELD and other modified MELD scores in predicting the risk of mortality. Our study supports the incorporation of serum albumin into the modified MELD score to provide additional risk information in patients with AHF.

The underlying mechanism is that venous congestion and hypoperfusion can contribute to elevated liver enzymes and creatinine, resulting in cardio–renal–hepatic syndrome [18]. The progression of liver
dysfunction in patients with AHF is complex and may follow any of several pathways. Biochemical markers of cholestasis, such as γ-glutamyl transpeptidase, bilirubin, and alkaline phosphatase, are increased in the plasma of AHF patients with elevated central venous pressure [19]. Hypoperfusion-induced hypoxic liver injury is also the major cause of massively elevated aminotransferase levels in patients with AHF, and the elevation of these levels is a risk factor for mortality [20]. In the setting of renal dysfunction, congestion was a stronger predictor of worsening renal function than cardiac output or mean arterial pressure in patients with AHF [21, 22]. Congestion is the main profile of diastolic dysfunction. Interestingly, a study also indicated that renal insufficiency is more important in determining the risk of mortality in patients with diastolic cardiac dysfunction than in those with systolic dysfunction [23]. The increase in central venous pressure is associated with worsen renal function through several mechanisms including the decrease in renal blood flow and interstitial fibrosis [24].

There are several limitations in our study. First, the empirically chosen Chinese population was a major limitation. Validation in other population should be performed to verify our results. Second, although we included a set of confounding factors and indicated the strong prognostic power of the MELD score and its modifications in patients with AHF, unmeasured cofounding factors may also play a role. Finally, the MELD score or its modifications are subject to laboratory variations, and previous oral medications such as diuretics can impact sodium and creatinine excretion, which could confound the results.

Conclusions

Quantifying liver and renal function using the MELD_albumin score in patients with acute heart failure assesses the risk of mortality more accurately than the commonly used MELD score or its other modifications.

Abbreviations

AHF, acute heart failure; ALT, alanine aminotransferase; AST, aspartate aminotransaminase; AUC, areas under the curve; BMI, body mass index; CI, confidence interval; HF, heart failure; HR, hazard ratio; INR, international normalized ratio; LVEF, left ventricular ejection fraction; MELD, model for end-stage liver disease; MELD_XI, MELD excluding the international normalized ratio; MELD_sodium, MELD including sodium; NYHA, New York Heart Association; proBNP, pro-brain natriuretic peptide; ROC, receiver operating characteristic;

Declarations

Ethics approval and consent to participate

The study was approved by the ethics committee of the First Affiliated Hospital of Nanjing Medical University, and all patients provided written informed consent. All procedures conformed to the standards
of the Declaration of Helsinki.

Consent for publication

Not applicable.

Competing interests

The authors have no conflict of interest to disclose.

Funding

The study was supported by the Twelve-Fifth National Key Technology R&D Program (2011BAI11B08).

Authors’ contributions

SGL and XLL conceived and supervised the study; XYL, IC and TY were responsible for data collection. WMY and HFZ were responsible for analysis of data; SGL drafted the manuscript; HFZ and XLL made manuscript revisions. All authors read and approved the final manuscript.

Acknowledgements

Not applicable.

References


Figures
Figure 1

Study flow chart.

Assessed for eligibility (n=590)

48 excluded:
- 46 cases underwent urgent surgery with severe valvar disease or coronary disease.
- 2 cases refused to participate

Enrolled (n=542)

Excluded
- Take oral anticoagulants on admission (n=46)

Total included (n=496)

Loss to follow up (n=30)

Data available for analyses (n=466)
Assessed for eligibility (n=590)

48 excluded:
- 46 cases underwent urgent surgery with severe valvular disease or coronary disease.
- 2 cases refused to participate

Enrolled (n=542)

Excluded
- Take oral anticoagulants on admission (n=46)

Total included (n=496)

Loss to follow up (n=30)

Data available for analyses (n=466)

**Figure 1**

Study flow chart.

Formulas used in the calculation of different MELD scores
MELD = 5.11 * ln(INR) + 3.78 * ln(Total Bilirubin) + 9.57 * ln (Creatinine) + 6.43
MELD-XI = 5.11 * ln(Total Bilirubin) + 11.76 * ln (Creatinine) + 9.44
MELD_albumin= 11.2 * ln (1) + 3.78 * ln(Total bilirubin) + 9.57 * ln (Creatinine) + 6.43 (Albumin≥4.1 g/dL)
MELD_albumin= 11.2 * ln [1+(4.1-Albumin)] + 3.78 * ln(Total Bilirubin) + 9.57 * ln (Creatinine) + 6.43 (Albumin<4.1 g/dL)
MELD_sodium= MELD - (Sodium mmol/l) - [0.025 * MELD * (140 - Sodium mmol/l)] + 140

**Figure 2**
The formulas for calculating the model for end-stage liver disease (MELD) score and modified MELD scores.

**Formulas used in the calculation of different MELD scores**

- **MELD**  \(= 5.11 \times \ln(INR) + 3.78 \times \ln(Total\ Bilirubin) + 9.57 \times \ln(Creatinine) + 6.43\)
- **MELD-XI**  \(= 5.11 \times \ln(Total\ Bilirubin) + 11.76 \times \ln(Creatinine) + 9.44\)
- **MELD\_albumin**  \(= 11.2 \times \ln(1 + 3.78 \times \ln(Total\ Bilirubin)) + 9.57 \times \ln(Creatinine) + 6.43\) (Albumin \(\geq 4.1\ g/dL\))
- **MELD\_albumin**  \(= 11.2 \times \ln[1 + (4.1 - \text{Albumin})] + 3.78 \times \ln(Total\ Bilirubin) + 9.57 \times \ln(Creatinine) + 6.43\) (Albumin \(< 4.1\ g/dL\))
- **MELD\_sodium**  \(= \text{MELD} - (\text{Sodium}\ mmol/l) - [0.025 \times \text{MELD} \times (140 - \text{Sodium}\ mmol/l)] + 140\)

**Figure 2**

The formulas for calculating the model for end-stage liver disease (MELD) score and modified MELD scores.

**Figure 3**
Quantitative distribution of the model for end-stage liver disease (MELD) score and its 3 modifications (A). Pairwise Spearman correlations among MELD score and its 3 modifications (B). ***، P<0.001.

**Figure 3**

Quantitative distribution of the model for end-stage liver disease (MELD) score and its 3 modifications (A). Pairwise Spearman correlations among MELD score and its 3 modifications (B). ***، P<0.001.
Figure 4

Time-dependent ROC analysis (A) and areas under the curve (B) of the model for end-stage liver disease (MELD) score and its 3 modifications for all-cause mortality.
Figure 4

Time-dependent ROC analysis (A) and areas under the curve (B) of the model for end-stage liver disease (MELD) score and its 3 modifications for all-cause mortality.
Figure 5

Time-dependent ROC analysis (A) and areas under the curve (B) of the model for end-stage liver disease (MELD) score and its 3 modifications for cardiovascular mortality.
Figure 5

Time-dependent ROC analysis (A) and areas under the curve (B) of the model for end-stage liver disease (MELD) score and its 3 modifications for cardiovascular mortality.